. No association between rs4845625 and stroke was observed in whites. The known chromosome 4 locus near PITX2 in whites also was associated with AF in African Americans (rs4611994; hazard ratio, 1.40; 95% CI, 1.16 -1.69; Pϭ0.0005). Conclusions-In a community-based cohort meta-analysis, we identified genetic association in IL6R with AF in whites.
results, it also leads to false-negatives. Biologically interesting associations may therefore fail to reach genome-wide significance. Such concerns provide the motivation for investigating a pathophysiologically focused gene panel to identify additional important genetic variants associated with AF. Substantial differences in AF prevalence have been observed between African Americans and whites of European descent. 4 The racial variation raises the possibility that the genetic basis of AF in African Americans is different from that in whites. 5 It is unknown if any of the single-nucleotide polymorphisms (SNPs) associated with AF in European ancestry populations are relevant to AF in African Americans.
Clinical Perspective on p 564
We related a gene-centric selection of cardiovascular candidate SNPs to AF data in 3 community-based cohorts of whites and African Americans participating in the Candidate Gene Association Resource (CARe) study, 6 and followed up our results in the German Competence Network for AF. 7 Because recent genome-wide genetic investigations indicated a potential relevance of genetic loci related to AF for stroke risk, 8, 9 we further examined our top finding in relation to incident stroke in the Heart and Aging Research in Genomic Epidemiology Stroke Consortium. 10 
Methods

Study Samples
The study design and methods of the CARe study have been described. 6 For AF analyses, the National Heart, Lung, and Blood Institute (NHLBI) discovery samples consisted of 3 prospective, communitybased cohorts from the United States with genotyping in individuals of European descent, the Atherosclerosis Risk In Communities study (ARIC, nϭ10 878), the Cardiovascular Health Study (CHS, nϭ3952), and the Framingham Heart Study (FHS, nϭ3694). Data in African Americans were available in ARIC (nϭ2,922) and CHS (nϭ740). Race/ethnicity was by self-report. DNA samples and phenotype information from the CARe cohorts were shipped to the Broad Institute of MIT and Harvard and deposited in the central database. Genotype quality control procedures were performed separately for each cohort. Control criteria comprised sex concordance of genotype-inferred sex and reported sex, missing SNP data, and genotyping success rate. SNPs with missing data greater than 10% and samples with call rates of less than 90% were discarded.
We followed up our top results in the German Competence Network for AF (AFNET, nϭ906), a national registry of AF cases (online-only Data Supplement Table I ). 7 Further information on study design, genotyping, and quality control for the discovery and follow-up samples is provided in the online-only Data Supplement (Methods and Supplementary Table I) .
Outcome Ascertainment
The outcome was initial, paroxysmal, persistent, or permanent AF or atrial flutter. 11 We combined analyses of incident AF and prevalent AF in the meta-analysis. For details on outcome ascertainment in the three cohorts, see the online-only Data Supplement.
Genotyping
We used a cardiovascular gene-centric 50K SNP IBC (ITMAT, Broad, and CARe) array for large-scale genomic association studies comprising 49 320 SNPs in 2095 genes (http://bmic.upenn.edu/cvdsnp/).
Statistical Analysis
Individuals with missing phenotype or genotype data and age Ͻ50 years at baseline were excluded. We chose the age cut-off because AF incidence is low under the age of 50. 12 For analyses of incident AF, participants with AF at baseline were excluded. Loss to follow-up was a censoring event. Studies with data available on heart surgery (ARIC, CHS) did not count AF events if coronary artery bypass grafting or valve surgery occurred during the same hospital stay.
We used additive genetic models and all analyses were performed separately by race. Analyses adjusted for age at DNA draw, sex, site (ARIC, CHS), or cohort (FHS). For analyses of prevalent AF, we performed logistic regression. In African Americans, analysis of prevalent AF was not performed due to a very small number of prevalent AF cases (nϭ38). Framingham applied a generalized estimating equation model to account for correlated family data. For incident AF, we used proportional hazards regression. The outcome was time to AF (or censor) from baseline. For Framingham data we used a robust variance estimate that accounts for familial correlation. We consistently used the allele that comes first in alphabetic order as the effect allele in our analyses.
We used an inverse variance-weighted meta-analysis approach to combine the regression parameter estimates of 5 analyses for whites across incident and prevalent AF and 2 analyses for African Americans. The martingale property of Cox models implies that the estimated regression coefficient for CHS (FHS) incident analysis is independent of the estimated regression coefficient for CHS (FHS) prevalent analysis, which justifies combining incident and prevalent results in the metaanalysis. In a previous genome-wide association study of AF, 2 associations were fairly consistent across the ARIC, CHS, and FHS cohorts.
An array-wide significance threshold of PϽ2ϫ10 Ϫ6 corresponds to an approximate Bonferroni correction of ␣ϭ0.05ϫ25 000 independent tests after accounting for the number of SNPs in linkage equilibrium on the IBC gene chip (see online-only Data Supplement for details). Genes with 2 or more SNPs meeting the following criteria were candidates to move forward to our replication study: (1) meta-analysis, PϽ0.001 and (2) same direction of effect for at least 4 of 5 analyses that contributed to the meta-analysis. Seven genes met these criteria, and we chose 1 SNP from each of these genes. For 6 of the genes, we selected the SNP with the smallest probability value. For 1 of the genes, we chose the SNP with the second-smallest probability value because it had a larger minor-allele frequency than the most significant SNP (36% instead of 15%). In AFNET, genome-wide association analyses were performed adjusting for age and sex, using logistic regression in relation to prevalent AF. Regression estimates and adjusted standard errors were combined using inverse-variance weighted meta-analysis. Quantile-quantile plots on the distribution of the observed and expected probability values are provided in online-only Data Supplement Figure I .
Secondary Analysis
In secondary analyses, we tried to understand whether the top locus in the IL6R gene located on the same chromosome as the known KCNN3 3 locus represented an independent signal. We compared the linkage disequilibrium (LD) structure for rs13376333 and the newly identified SNP rs4845625 in HapMap and the available 1000 Genomes database (http://www.1000genomes.org). In addition, we estimated the proportion of individuals who had risk alleles from both loci by imputing genotypes, using additional genome-wide genotyping data in the 3 cohorts (ARIC, nϭ9044; CHS, nϭ3204; FHS, nϭ4404). 2, 3 The imputation quality (observed/expected variance) for the 2 SNPs was good and ranged from 0.83-0.99. Framingham Heart Study data included related individuals. We also provide Pearson correlation coefficients between genotypes.
We further tested the association of the top finding with incident ischemic stroke in silico in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Stroke Consortium. The consortium incorporates individuals from ARIC, CHS, and FHS as well as from the Rotterdam Study with genome-wide data (nϭ19 602 whites). Study design and methods have been reported earlier. 10 We applied an inverse variance fixed-effects meta-analysis to combine the study data. Further details are provided in the online-only Data Supplement.
Results
Study cohorts included a total of 22 186 participants (55.9% women; 16.5% African Americans). In whites, analyses were based on 389 prevalent AF cases and 1871 incident AF events over a total of 218 297 person-years of follow-up and in African Americans on 263 incident AF events in over 56869 personyears. Details on the characteristics of the discovery and follow-up cohorts are provided in Table 1 and online-only Data  Supplement Table II . In whites, only the previously reported region on chromosome 4 neighboring the PITX2 gene reached our predefined significance threshold with the SNP rs2200733, relative risk (RR) T allele, 1.40; 95% confidence interval (CI), 1.29 to 1.51; Pϭ2.5ϫ10
Ϫ16
. rs2200733 showed modest significance, Pϭ0.002 in African Americans (Table 2, results by  cohort, online-only Data Supplement Table III) . From the 3 cohorts of white individuals, we carried forward 7 SNPs with meta-analysis PϽ0.001 and effect estimates in the same direction in at least 4 of the 5 analyses for additional follow-up in silico testing in AFNET, 3 Table VI) .
In secondary analyses, we assessed the relation between the previously described KCNN3 and the novel IL6R locus. For participants in the present study, Pearson correlation coefficients between genotypes in the three cohorts ranged from Ϫ0.015 to Ϫ0.019 in individuals of European descent and from 0.01 to 0.075 in AF cases. The proportion of individuals with at least one risk allele in KCNN3 and at least 1 risk allele in IL6R was 0.34 in the total sample and 0.39 in individuals with AF.
Discussion
Principal Findings
In our large-scale candidate gene approach assessing approximately 2000 genes across 3 community-based cohorts in relation to AF in 2 races, top SNPs were located in the region of recent findings from genome-wide analyses in whites. We further extended the knowledge on the association of the known chromosome 4 locus in whites toward African Americans. In addition, we identified an intronic SNP in the IL6R gene in association with AF risk. We present several additional plausible genes of interest for follow-up in African Americans.
A novel finding of interest is the association with the IL6R gene region in relation to AF. There has been controversy regarding inflammation's role as a causative agent or a risk Values are mean (SD), or n (%).
marker in AF. [13] [14] [15] [16] Levels of circulating interleukin-6, along with levels of other proinflammatory molecules such as C-reactive protein and fibrinogen, have consistently been associated with AF. 13, 17 Recent investigations of genetic variation of the IL6 gene also provide suggestive evidence (but without replication) for the role of the interleukin-6 system in the pathophysiology of AF. 18 A correlation between nearby SNPs, for example, the exonic SNP rs8192284 in the IL6R gene and interleukin-6 receptor concentrations, interleukin-6, and other inflammatory biomarkers such as C-reactive protein and fibrinogen has been demonstrated, 19, 20, 20, 21 as well as metabolic syndrome pathways. 22 Diseases also associated with genetic variation at the IL6R locus and closely related to AF are diabetes and coronary artery disease. 23, 24 As intermediate risk factors they may provide a link between the polymorphisms and AF. If additional research confirms that variation in IL6R is indeed related to development of AF, the interleukin-6 pathway might become an experimental target for modulating the inflammatory milieu to modify AF risk.
A recent investigation identified an association between a KCNN3 locus and lone AF. 3 KCNN3 is located about 400 kb downstream of IL6R. However, the LD between the top KCNN3 SNP (rs13376333) and the IL6R SNP in HapMap release 22 is very small, with r 2 ϭ0.008 in CEU and r 2 ϭ0.001 in YRI. Similarly, in the preliminary 1000 Genomes data (http://www.1000genomes.org), the corresponding r 2 values are 0.012 in CEU and 0.005 in YRI. The publicly available results were recapitulated in our data with correlation coefficients from Ϫ0.019 to 0.075. Because of the low correlation the IL6R finding appears to represent an independent signal. Prevalent AF is accompanied by a measurably elevated inflammatory state. 13, 25 It can be argued that the predictive value of indicators of inflammation may be due to undetected episodes of AF. Recurrent, asymptomatic AF might thus be associated with elevated inflammatory activity before the diagnosis of AF. Reverse causation is not possible in the setting of genetic association with disease. Our findings may thus provide evidence for a potential causal role of the interleukin-6 pathway.
Recent observations that genetic loci associated with AF also may be risk indicators for stroke events 8, 9 led to the hypothesis that rs4845625 may be related to incident stroke. The assumption of an association was supported by consistent data on the interplay of genetic variation at the IL6R locus and circulating interleukin-6 concentrations, 20 and observations that interleukin-6 levels were related to cardiovascular events such as stroke. 21, 26 However, we did not observe an association for the top SNP with ischemic stroke in the large CHARGE stroke consortium. One explanation might be that we did not focus on stroke subtypes because differential associations for atherothrombotic and cardioembolic brain infarction have been observed. 27 Unfortunately, our current investigation is underpowered for analysis of ischemic stroke subtypes.
Race
Whereas risk factor associations with AF are similar in whites and African Americans, 28, 29 AF risk factor burden is higher in African Americans, but prevalence and incidence of AF are lower compared to individuals of European descent. 28 These observations suggest AFNET indicates German Competence Network on Atrial Fibrillation; CARe, Candidate Gene Association Resource; EAF, effect allele frequency; OR, odds ratio; RR, relative risk; SE, standard error; and SNP, single-nucleotide polymorphism.
*Range of EAFs across cohorts. Analyses were modeled for the alleles in alphabetical order. The effect allele was the allele earlier in the alphabet.
risk factors beyond classic risk indicators, and differences in genetic predisposition have been proposed. 5, 28, 29 Though none of the SNPs in African Americans reached array-wide significance in our analysis, the chromosome 4 locus, an established AF susceptibility locus in whites, was among the strongest associations. The comparable effect estimate in African Americans suggests genetic similarities between the two races at this specific locus. Other recently reported SNPs in association with AF in whites at the ZFHX3 and KCNN3 loci 2, 3 were not represented on the IBC chip. Among SNPs with PϽ0.001, we identified several potassium channel-related genes including KCNQ1 (rs463535), KCNA5 Apart from the chromosome 4 locus, top results differed by race and associations did not consistently appear in the same direction in African Americans and whites in the current setting, indicating a high probability of false-positives due to a limited number of AF events and different linkage patterns in African Americans, rather than true differences by race. Overall, our results in African Americans should be interpreted with caution and viewed as hypothesis-generating.
Strengths and Limitations
Strengths of the study include the careful AF ascertainment in the cohorts, phenotype harmonization across cohorts, centralized high quality genotyping, uniform quality control, and statistical analysis. We present results for a large sample of African American participants with genetic data in relation to AF. Follow-up with additional African American samples is necessary in the future when genetic data and AF events data from other studies become available.
Our a priori selected significance threshold mimics the strategy used in genome-wide association studies. It is based on the assumption of homogenous LD. Although this assumption is questionable, independent replication data were used to protect against false-positive findings. The public deposition of the genetic association data will provide a unique resource for future studies in whites and African Americans. Whereas it is biologically plausible that the IL6R locus provides support for an inflammatory contribution to AF, we acknowledge that the identified SNP may not be causally related to AF or may be in LD with a causal SNP. We also note that our findings may not be generalizable to other ethnicities/races, such as individuals of Asian ancestry. As noted above, our data do not provide support for a large contribution of rs4845625 to stroke. However, we cannot exclude that rs4845625 may have a small effect size in relation to stroke or may be related to specific stroke subtypes.
In conclusion, we identified a novel association between variation in a SNP in the IL6R gene and AF. The association is biologically plausible and may stimulate future research. In addition, we demonstrated that the chromosome 4q25 AF susceptibility locus, originally discovered in whites, is associated with AF in African Americans.
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SUPPLEMENTAL MATERIAL ARIC (Atherosclerosis Risk in Communities):
Atrial fibrillation (AF) in ARIC was ascertained from three different sources: electrocardiograms (ECGs), hospitalizations, and death certificates. Study participants underwent 12-lead ECG at baseline and at each followup exam (3 exams; one exam every 3 years). As part of standard follow-up procedures, trained abstractors obtained and recorded all ICD-9 hospital discharge diagnosis from participant's hospitalizations reported in annual follow-up interviews and from surveillance of local hospitals. AF was defined as presence of ICD-9 code 427.31 or 427.32 in the discharge codes. AF that occurred during the same hospital stay as coronary artery bypass surgery or valve surgery was not included as an AF event. In addition, ARIC participants were classified as AF cases if AF was listed as one of the diagnoses in the death certificate (ICD-10 code I48 or ICD-9 code 427.3). 1 CHS (Cardiovascular Health Study): CHS participants had a resting 12-lead ECG at the baseline clinic visit. Participants were contacted every 6 months, with clinic visits alternating with telephone contacts, during up to 15 years' follow-up. A resting 12-lead ECG was performed at each annual clinic visit through 1999. At each follow-up contact, participants were asked to report all hospitalizations since the last contact, and hospital discharge summaries were routinely obtained. In addition, hospital discharge International Classification of Disease, 9
th Revision (ICD-9) codes for all participants were obtained from Medicare and later from the Centers for Medicare and Medicaid Services. A review of the first 212 discharge summaries for hospitalizations with an ICD-9 code for atrial fibrillation or flutter (427.3x) in any position revealed a high positive predictive value (209 of 212, 98.6%); therefore, a hospital discharge ICD-9 code for AF was accepted as valid for subsequent cases. In CHS, the diagnosis of AF was made if atrial fibrillation or flutter was present on an annual clinic visit ECG between 1989 and 1999, or when a hospital discharge ICD-9 code for atrial fibrillation or flutter was present in any position. Prevalent AF was defined as AF on the baseline ECG. The date of incident AF was taken as the earlier of the date of the clinic visit for AF identified on clinic ECG, or the date of hospital admission for AF identified from hospital discharge diagnosis. AF that occurred during the same hospital stay as coronary artery bypass surgery or valve surgery was not included as an AF event.
FHS (Framingham Heart Study):
The diagnosis of AF was made if atrial fibrillation or flutter was present on an electrocardiogram derived from hospital or outpatient records or on a Framingham Study clinic tracing. 2 Since January, 2000 biennial health history update calls included a routine question as to whether the participant had experienced interim AF. If AF was reported at the main examination or on health history update, outside records were routinely sought. All incident AF cases underwent a review by two of three Framingham cardiologists. If AF was recorded by history only, two investigators had to agree that the evidence for the presence of AF was compelling (cardioversion or institution of anticoagulant or of antiarrhythmic medication). The categorization of incident vs. prevalent AF was based on the time to event from blood draw. A diagnosis of AF on the day of blood draw or earlier led to the designation of prevalent AF.
All studies were approved by their institutional review boards from the participating institutions. Appropriate material transfer and data distribution agreements were signed under the approval of the local institutional review boards. Participants provided written informed consent in the respective cohorts. The authors had full access to the data and take responsibility for its integrity. All authors have read and agree to the manuscript as written.
Replication
Patients from the AFNET (German Competence Network for Atrial Fibrillation), a national registry of AF cases served as the replication sample. The structure and design of the sample have been reported earlier. 5 DNA samples were available from patients with AF onset before age 60 years. AF was diagnosed if AF was present on an electrocardiogram analyzed by a trained physician. Exclusion criteria comprised signs of moderate to severe heart failure, moderate to severe valvular heart disease or hyperthyroidism. Controls aged 25-74 years were drawn from the KORA S4 study, 6 and did not have a history of AF, or cardiac disease such as myocardial infarction, heart failure or valve disease and needed to be in sinus rhythm at the time of blood draw.
Stroke association
The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Stroke Consortium 7 comprise individuals with genome-wide genotype data in ARIC, CHS, FHS and the Rotterdam Study. The latter is a population-based cohort of inhabitants of the Rotterdam district Ommoord. It is designed to investigate the determinants of health and disease in individuals 55 years of age or older with a special focus on neurogeriatric and cardiovascular disease. 8 The outcome was defined as a focal neurologic deficit characterized by a sudden onset and lasting for a minimum of 24 hours or until death if the patient died within one day of symptom onset. Details on the outcome ascertainment in the four studies have been published. [9] [10] [11] [12] Stroke events were classified as ischemic, hemorrhagic, or unknown based on clinical and imaging criteria. For our current analyses we evaluated ischemic stroke events.
All participating cohorts and their AF samples have been described in more detail in recent publications.
1-5,7
Genotyping and Quality Control Criteria
Genotyping in the CARe cohorts was conducted using a cardiovascular gene-centric 50K SNP IBC (ITMAT, Broad, and CARe) array for large-scale genomic association studies (http://bmic.upenn.edu/cvdsnp/) comprising over 50,000 single nucleotide polymorphisms in 2095 genes. 13 Genotyping and quality control were centrally performed at the Broad Institute.
In each cohort, genotype quality control procedures were performed separately. Main control criteria included sex concordance of genotype-inferred sex and reported sex, missing SNP data and genotyping success rate. We discarded samples with call rates of less than 90% and SNPs with missing data greater than 10%. In the family-based FHS, individuals from families accounting for relevant Mendelian errors were excluded. Quality control was performed using PLINK. 14 Genotyping information and quality control criteria for AFNET are provided in Supplementary Table 1 .
The CHARGE Stroke Consortium cohorts used the following gene chips: GeneChip SNP Array 6.0 (Affymetrix) (ARIC), HumanCNV370-Duo (Illumina) (CHS), Gene-Chip Human Mapping 500K Array Set and 50K Human Gene Focused Panel (Affymetrix) (FHS) , and version 3.0 of the Infinium HumanHap550 chip (Illumina) (Rotterdam). The top SNP was imputed in stroke consortium data. Imputation quality assessed by comparing the observed dosage variance to the expected variance under Hardy-Weinberg equilibrium was good for rs4845625 (0.98-0.99 across cohorts). Detailed genotyping information and quality control steps have been published.
Statistical significance
We applied an a priori selected array-wide significance threshold of P<2x10 -6 across cohorts which corresponds to an approximate Bonferroni correction of alpha=0.05 by 25,000 independent tests after accounting for the number of SNPs in linkage equilibrium on the IBC genotyping platform. To assess the number of independent loci represented by the IBC chip, linkage disequilibrium was determined through the linkage disequilibrium pruning option in PLINK. 14 
